^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Ubiquitin pathway modulator

    Related drugs:
    2d
    A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Pfizer | Trial completion date: Sep 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    vepdegestrant (ARV-471)
    29d
    A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults. (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Pfizer
    New P1 trial
    |
    vepdegestrant (ARV-471)
    1m
    A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults (clinicaltrials.gov)
    P1, N=52, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    vepdegestrant (ARV-471)
    2ms
    A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Pfizer | Trial completion date: Mar 2024 --> Sep 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    vepdegestrant (ARV-471)
    2ms
    Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography-Tandem Mass Spectrometry. (PubMed, Molecules)
    We developed and validated a sensitive and rapid liquid chromatography-tandem mass spectrometry method to quantify vepdegestrant in rodent plasma using bavdegalutamide (formerly ARV-110) as an internal standard. In liver microsomes, vepdegestrant exhibited moderate stability in rats but was stable in mice, dogs, and humans. These findings enhance the understanding of pharmacokinetic properties of vepdegestrant supporting further development of PROTAC drugs.
    PK/PD data • Preclinical • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    bavdegalutamide (ARV-110) • vepdegestrant (ARV-471)
    2ms
    TACTIVE-N: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (clinicaltrials.gov)
    P2, N=152, Completed, Arvinas Inc. | Active, not recruiting --> Completed
    Trial completion • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    anastrozole • vepdegestrant (ARV-471)
    3ms
    VERITAC-2: A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (clinicaltrials.gov)
    P3, N=560, Recruiting, Pfizer | Trial primary completion date: Aug 2024 --> Nov 2024
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    fulvestrant • vepdegestrant (ARV-471)
    4ms
    VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. (PubMed, Future Oncol)
    Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and ESR1 mutation-positive subpopulation. Secondary end points include overall survival, tumor response, safety, pharmacokinetics, patient-reported outcomes, and circulating tumor DNA biomarkers.Clinical trial registration: NCT05654623 (ClinicalTrials.gov).
    P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    fulvestrant • vepdegestrant (ARV-471)
    4ms
    A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    vepdegestrant (ARV-471)
    5ms
    VERITAC-3: A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=1180, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Ibrance (palbociclib) • letrozole • vepdegestrant (ARV-471)
    6ms
    A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant (clinicaltrials.gov)
    P1, N=12, Completed, Pfizer | Recruiting --> Completed
    Trial completion
    |
    vepdegestrant (ARV-471)
    6ms
    Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. (PubMed, Clin Cancer Res)
    Vepdegestrant achieved greater ER degradation in-vivo compared to fulvestrant, which correlated with improved tumor growth inhibition, suggesting vepdegestrant could be a more effective backbone ET for patients with ER+/HER2- breast cancer.
    Preclinical • Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • vepdegestrant (ARV-471) • Itovebi (inavolisib)
    6ms
    A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=22, Terminated, Celgene | Trial completion date: Oct 2025 --> Apr 2024 | Active, not recruiting --> Terminated; Business objectives have changed.
    Trial completion date • Trial termination • Combination therapy
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • eragidomide (CC-90009)
    6ms
    C4891039: A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam (clinicaltrials.gov)
    P1, N=15, Completed, Pfizer | Recruiting --> Completed
    Trial completion
    |
    vepdegestrant (ARV-471) • midazolam hydrochloride
    6ms
    A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P1, N=101, Terminated, Celgene | Trial completion date: Jul 2025 --> Apr 2024 | Active, not recruiting --> Terminated; Trial terminated because of lack of efficacy in the short term acute phase.
    Trial completion date • Trial termination
    |
    eragidomide (CC-90009)
    6ms
    ARV-471-mBC-101: A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Arvinas Estrogen Receptor, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • vepdegestrant (ARV-471)
    7ms
    A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults (clinicaltrials.gov)
    P1, N=48, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepdegestrant (ARV-471)
    7ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Pfizer | Trial completion date: Aug 2027 --> Jan 2027 | Trial primary completion date: Feb 2027 --> Jul 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • samuraciclib (CT7001)
    7ms
    A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Pfizer
    New P1 trial
    |
    vepdegestrant (ARV-471)
    8ms
    C4891039: A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam (clinicaltrials.gov)
    P1, N=16, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepdegestrant (ARV-471) • midazolam hydrochloride
    8ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Pfizer | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • samuraciclib (CT7001)
    8ms
    A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant (clinicaltrials.gov)
    P1, N=12, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepdegestrant (ARV-471)
    8ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) (clinicaltrials.gov)
    P1/2, N=47, Recruiting, Pfizer | Phase classification: P1b/2 --> P1/2 | N=35 --> 47 | Trial completion date: Oct 2027 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • vepdegestrant (ARV-471)
    9ms
    A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Feb 2026 | Trial primary completion date: May 2026 --> Aug 2025
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • atirmociclib (PF-07220060)
    9ms
    A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Celgene | Phase classification: P1/2 --> P1
    Phase classification
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • eragidomide (CC-90009)
    9ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Pfizer | Phase classification: P2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • samuraciclib (CT7001)
    9ms
    A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Pfizer
    New P1 trial
    |
    vepdegestrant (ARV-471)
    9ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Pfizer | Phase classification: P1b/2 --> P1/2 | Trial completion date: Jun 2027 --> Dec 2025
    Phase classification • Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • vepdegestrant (ARV-471)
    9ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov)
    P2, N=67, Recruiting, Pfizer
    New P2 trial • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • samuraciclib (CT7001)
    9ms
    A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Pfizer
    New P1 trial
    |
    vepdegestrant (ARV-471) • midazolam hydrochloride
    10ms
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov)
    P2, N=67, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepdegestrant (ARV-471) • samuraciclib (CT7001)
    10ms
    Annual review of PROTAC degraders as anticancer agents in 2022. (PubMed, Eur J Med Chem)
    As of the end of 2022, more than 20 drugs have entered clinical trials, with ARV-471 targeting estrogen receptor (ER) showing remarkable progress by entering phase III clinical studies...In this review, we aimed to update the PROTAC degraders as potential anticancer agents covering articles published in 2022. The design strategies, degradation effects, and anticancer activities were highlighted, which might provide an updated sight to develop novel PROTAC degraders with great potential as anticancer agents as well as favorable drug-like properties.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • BRD4 (Bromodomain Containing 4) • CDK9 (Cyclin Dependent Kinase 9)
    |
    KRAS mutation
    |
    vepdegestrant (ARV-471)
    10ms
    TACTIVE-E: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Arvinas Estrogen Receptor, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b --> P1
    Enrollment closed • Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    everolimus • vepdegestrant (ARV-471)
    10ms
    TACTIVE-N: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (clinicaltrials.gov)
    P2, N=152, Active, not recruiting, Arvinas Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    anastrozole • vepdegestrant (ARV-471)
    10ms
    A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Pfizer | Trial primary completion date: Nov 2023 --> Mar 2024
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    vepdegestrant (ARV-471)
    10ms
    PK: A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants (clinicaltrials.gov)
    P1, N=12, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    vepdegestrant (ARV-471)
    10ms
    A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=65, Not yet recruiting, Pfizer
    New P1/2 trial • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • atirmociclib (PF-07220060)
    10ms
    A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=22, Active, not recruiting, Celgene | Phase classification: P1b --> P1/2 | N=76 --> 22
    Phase classification • Enrollment change • Combination therapy
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • eragidomide (CC-90009)
    12ms
    PK: A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    vepdegestrant (ARV-471)
    1year
    Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene. (PubMed, PLoS One)
    Induction of full-length Rb protein was potentiated by the cereblon E3 ligase modulator CC-90009. These results suggest that pharmacological induction of translational readthrough could be a feasible strategy for therapeutic targeting of tumors with nonsense mutant RB1.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • CRBN (Cereblon)
    |
    RB1 mutation
    |
    eragidomide (CC-90009)
    1year
    TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer (SABCS 2023)
    The cyclin-dependent kinase (CDK)4/6 inhibitors abemaciclib and ribociclib are approved in combination with an aromatase inhibitor or fulvestrant, or as monotherapy (abemaciclib), for ER+/HER2- advanced or metastatic breast cancer...Vepdegestrant is being evaluated in combination with abemaciclib (sub-study A; NCT05548127), ribociclib (sub-study B; NCT05573555), and samuraciclib (sub-study C)...The phase 2 portion of each sub-study will further evaluate the antitumor activity of the combinations; the primary endpoint is objective response and secondary endpoints include antitumor activity (CBR and DOR), PFS, overall survival, safety, plasma concentration of study drugs, and changes in circulating tumor DNA. Future combination sub-studies will be included in TACTIVE-U.
    P1/2 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • vepdegestrant (ARV-471) • samuraciclib (CT7001)
    1year
    VERITAC-3: A randomized phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (SABCS 2023)
    Eligible patients (aged ≥18 years) must have histologically or cytologically confirmed ER+/HER2- locoregionally recurrent or metastatic breast cancer, with no prior treatment in the advanced setting, and no prior treatment in any setting with CDK4/6 inhibitors, vepdegestrant, fulvestrant, elacestrant, or other investigational agents (including novel endocrine therapy, selective ER degraders, selective ER covalent antagonists, and complete ER antagonists). The primary efficacy endpoint of the phase 3 portion is progression-free survival based on blinded independent central review. Enrollment began June 2023 and is ongoing.
    Clinical • P3 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • Orserdu (elacestrant) • vepdegestrant (ARV-471)